Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Bishop, MR; Dickinson, M; Purtill, D; Barba, P; Santoro, A; Hamad, N; Kato, K; Sureda, A; Greil, R; Thieblemont, C; Morschhauser, F; Janz, M; Flinn, I; Rabitsch, W; Kwong, YL; Kersten, MJ; Minnema, MC; Holte, H; Chan, EHL; Martinez-Lopez, J; Muller, AMS; Maziarz, RT; McGuirk, JP; Bachy, E; Le Gouill, S; Dreyling, M; Harigae, H; Bond, D; Andreadis, C; McSweeney, P; Kharfan-Dabaja, M; Newsome, S; Degtyarev, E; Awasthi, R; del Corral, C; Andreola, G; Masood, A; Schuster, SJ; Jager, U; Borchmann, P; Westin, JR.

N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14.

https://pubmed.ncbi.nlm.nih.gov/34904798/